Reviva Pharmaceuticals Holdings (RVPH)
NASDAQ:RVPH
Total Valuation
Reviva Pharmaceuticals Holdings has a market cap or net worth of $10.12M. The enterprise value is -$14.03T.
Market Cap$10.12M
Enterprise Value-$14.03T
Share Statistics
Reviva Pharmaceuticals Holdings has 12,810,377 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding12,810,377
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Reviva Pharmaceuticals Holdings’s return on equity (ROE) is -2.30 and return on invested capital (ROIC) is -223.09%.
Return on Equity (ROE)-2.30
Return on Assets (ROA)-1.25
Return on Invested Capital (ROIC)-223.09%
Return on Capital Employed (ROCE)-2.34
Revenue Per Employee0.00
Profits Per Employee-1.42T
Employee Count14
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Reviva Pharmaceuticals Holdings is ―. Reviva Pharmaceuticals Holdings’s PEG ratio is <0.00001.
PE Ratio―
PS Ratio0.00
PB Ratio<0.01
Price to Fair Value<0.01
Price to FCF>-0.01
Price to Operating Cash Flow>-0.01
PEG Ratio<0.00001
Income Statement
In the last 12 months, Reviva Pharmaceuticals Holdings had revenue of 0.00 and earned -19.86T in profits. Earnings per share was -5.48.
Revenue0.00
Gross Profit0.00
Operating Income-20.20T
Pretax Income-19.85T
Net Income-19.86T
EBITDA-20.20T
Earnings Per Share (EPS)-5.48
Cash Flow
In the last 12 months, operating cash flow was -24.59T and capital expenditures 0.00, giving a free cash flow of -24.59T billion.
Operating Cash Flow-24.59T
Free Cash Flow-24.59T
Free Cash Flow per Share-1.92M
Dividends & Yields
Reviva Pharmaceuticals Holdings pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.61
52-Week Price Change-93.21%
50-Day Moving Average3.47
200-Day Moving Average8.02
Relative Strength Index (RSI)24.85
Average Volume (3m)14.40M
Important Dates
Reviva Pharmaceuticals Holdings upcoming earnings date is May 18, 2026, TBA (Confirmed).
Last Earnings DateMar 30, 2026
Next Earnings DateMay 18, 2026
Ex-Dividend Date―
Financial Position
Reviva Pharmaceuticals Holdings as a current ratio of 2.08, with Debt / Equity ratio of 4.71%
Current Ratio2.08
Quick Ratio2.08
Debt to Market Cap20.10K
Net Debt to EBITDA0.69
Interest Coverage Ratio1.51K
Taxes
In the past 12 months, Reviva Pharmaceuticals Holdings has paid 18.89B in taxes.
Income Tax18.89B
Effective Tax Rate>-0.01
Enterprise Valuation
Reviva Pharmaceuticals Holdings EV to EBITDA ratio is 0.69, with an EV/FCF ratio of 0.57.
EV to Sales0.00
EV to EBITDA0.69
EV to Free Cash Flow0.57
EV to Operating Cash Flow0.57
Balance Sheet
Reviva Pharmaceuticals Holdings has $14.44T in cash and marketable securities with $406.88B in debt, giving a net cash position of $14.03T billion.
Cash & Marketable Securities$14.44T
Total Debt$406.88B
Net Cash$14.03T
Net Cash Per Share$1.10M
Tangible Book Value Per Share$2.38M
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Reviva Pharmaceuticals Holdings is $15.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$15.50
Price Target Upside1862.03% Upside
Analyst ConsensusModerate Buy
Analyst Count4
Revenue Growth Forecast―
EPS Growth Forecast58.55%